WallStSmart

Humana Inc (HUM)vsProgyny Inc (PGNY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Humana Inc generates 9962% more annual revenue ($129.66B vs $1.29B). PGNY leads profitability with a 4.5% profit margin vs 0.9%. HUM trades at a lower P/E of 17.5x. HUM earns a higher WallStSmart Score of 58/100 (C).

HUM

Buy

58

out of 100

Grade: C

Growth: 5.3Profit: 4.0Value: 7.3Quality: 8.5
Piotroski: 4/9Altman Z: 4.37

PGNY

Hold

50

out of 100

Grade: D+

Growth: 7.3Profit: 6.0Value: 7.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.94
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HUMSignificantly Overvalued (-162.4%)

Margin of Safety

-162.4%

Fair Value

$66.84

Current Price

$174.24

$107.40 premium

UndervaluedFair: $66.84Overvalued
PGNYUndervalued (+16.6%)

Margin of Safety

+16.6%

Fair Value

$25.84

Current Price

$17.75

$8.09 discount

UndervaluedFair: $25.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HUM4 strengths · Avg: 9.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Altman Z-ScoreHealth
4.3710/10

Safe zone — low bankruptcy risk

PEG RatioValuation
0.998/10

Growing faster than its price suggests

P/E RatioValuation
17.5x8/10

Attractively priced relative to earnings

PGNY3 strengths · Avg: 8.7/10
Altman Z-ScoreHealth
4.9410/10

Safe zone — low bankruptcy risk

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

EPS GrowthGrowth
20.6%8/10

Earnings expanding 20.6% YoY

Areas to Watch

HUM4 concerns · Avg: 2.5/10
Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

Profit MarginProfitability
0.9%3/10

0.9% margin — thin

EPS GrowthGrowth
-59.3%2/10

Earnings declined 59.3%

Free Cash FlowQuality
$-1.85B2/10

Negative free cash flow — burning cash

PGNY3 concerns · Avg: 3.3/10
P/E RatioValuation
27.8x4/10

Moderate valuation

Market CapQuality
$1.48B3/10

Smaller company, higher risk/reward

Profit MarginProfitability
4.5%3/10

4.5% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : HUM

The strongest argument for HUM centers on Price/Book, Altman Z-Score, PEG Ratio. Revenue growth of 11.3% demonstrates continued momentum. PEG of 0.99 suggests the stock is reasonably priced for its growth.

Bull Case : PGNY

The strongest argument for PGNY centers on Altman Z-Score, Price/Book, EPS Growth.

Bear Case : HUM

The primary concerns for HUM are Return on Equity, Profit Margin, EPS Growth. Thin 0.9% margins leave little buffer for downturns.

Bear Case : PGNY

The primary concerns for PGNY are P/E Ratio, Market Cap, Profit Margin. Thin 4.5% margins leave little buffer for downturns.

Key Dynamics to Monitor

PGNY carries more volatility with a beta of 1.01 — expect wider price swings.

HUM is growing revenue faster at 11.3% — sustainability is the question.

PGNY generates stronger free cash flow (49M), providing more financial flexibility.

Monitor HEALTHCARE PLANS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

HUM scores higher overall (58/100 vs 50/100) and 11.3% revenue growth. PGNY offers better value entry with a 16.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Humana Inc

HEALTHCARE · HEALTHCARE PLANS · USA

Humana Inc. is a for-profit American health insurance company based in Louisville, Kentucky.

Visit Website →

Progyny Inc

HEALTHCARE · HEALTHCARE PLANS · USA

Progyny, Inc., a benefits management company, specializes in fertility benefits and family development solutions for employers in the United States. The company is headquartered in New York, New York.

Want to dig deeper into these stocks?